Bronchopulmonary Dysplasia Pipeline Drugs Insights Report 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight's, "Bronchopulmonary Dysplasia Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the Bronchopulmonary Dysplasia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bronchopulmonary Dysplasia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Bronchopulmonary Dysplasia Research. Learn more about our innovative pipeline today! @ Bronchopulmonary Dysplasia Pipeline Outlook- https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Bronchopulmonary Dysplasia Pipeline Report
• On 27 August 2025, OHB Neonatology Ltd. announced a study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
• DelveInsight's Bronchopulmonary Dysplasia pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Bronchopulmonary Dysplasia treatment.
• The leading Bronchopulmonary Dysplasia Companies such as Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc. and others.
• Promising Bronchopulmonary Dysplasia Pipeline Therapies such as Zelpultide alfa, Inhaled Nitric
• Oxide, Sildenafil, Pneumostem®, Curosurf, OHB-607, Infasurf, Palivizumab and others.

Download for updates and be a part of the revolution in Respiratory Diseases Care @ Bronchopulmonary Dysplasia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bronchopulmonary Dysplasia Emerging Drugs Profile
• AT-100: Airway Therapeutics, Inc
Zelpultide alfa, also known as AT-100, is a novel biologic developed by Airway Therapeutics, Inc. It is a recombinant version of the human surfactant protein D (rhSP-D), engineered to reduce inflammation and infection while modulating the immune response. This therapeutic candidate primarily targets bronchopulmonary dysplasia (BPD). Currently, the drug is in the Phase III stage of its development for the treatment of Bronchopulmonary dysplasia.

• OHB-607: Oak Hill Bio
OHB-607, previously known as TAK-607, is a novel therapeutic candidate developed by Oak Hill Bio, aimed at addressing significant health challenges faced by extremely premature infants. This investigational drug is a recombinant version of insulin-like growth factor 1 (IGF-1), combined with its binding protein IGFBP-3. It is specifically designed to prevent bronchopulmonary dysplasia (BPD). OHB-607 aims to restore IGF-1 levels to those typically present in full-term pregnancies, thereby supporting the normal growth and development of vital organs like the lungs, brain, and eyes. Currently, the drug is in the Phase II stage of its development for the treatment of Bronchopulmonary dysplasia.

The Bronchopulmonary Dysplasia Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Bronchopulmonary Dysplasia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchopulmonary Dysplasia Treatment.
• Bronchopulmonary Dysplasia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Bronchopulmonary Dysplasia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchopulmonary Dysplasia market.

Learn more about Bronchopulmonary Dysplasia Drugs opportunities in our groundbreaking Bronchopulmonary Dysplasia research and development projects @ Bronchopulmonary Dysplasia Unmet Needs- https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bronchopulmonary Dysplasia Companies
Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc. and others.

Bronchopulmonary Dysplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Bronchopulmonary Dysplasia Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay informed about how we're transforming the future of Respiratory Disease @ Bronchopulmonary Dysplasia Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Bronchopulmonary Dysplasia Pipeline Report
• Coverage- Global
• Bronchopulmonary Dysplasia Companies- Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc. and others.
• Bronchopulmonary Dysplasia Pipeline Therapies- Zelpultide alfa, Inhaled Nitric Oxide, Sildenafil, Pneumostem®, Curosurf, OHB-607, Infasurf, Palivizumab and others.
• Bronchopulmonary Dysplasia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Bronchopulmonary Dysplasia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Bronchopulmonary Dysplasia Pipeline on our website @ Bronchopulmonary Dysplasia Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Bronchopulmonary Dysplasia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Bronchopulmonary Dysplasia- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. AT-100: Airway Therapeutics, Inc
9. Mid Stage Products (Phase II)
10. OHB-607: Oak Hill Bio
11. Early Stage Products (Phase I)
12. Drug Name: Company Name
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Bronchopulmonary Dysplasia Key Companies
17. Bronchopulmonary Dysplasia Key Products
18. Bronchopulmonary Dysplasia- Unmet Needs
19. Bronchopulmonary Dysplasia- Market Drivers and Barriers
20. Bronchopulmonary Dysplasia- Future Perspectives and Conclusion
21. Bronchopulmonary Dysplasia Analyst Views
22. Bronchopulmonary Dysplasia Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.